Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-09-26
2006-09-26
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S069100, C435S235100
Reexamination Certificate
active
07112330
ABSTRACT:
Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production conformational antibodies against both L1 proteins upon administration to mice.
REFERENCES:
patent: 5855891 (1999-01-01), Lowy et al.
patent: WO 96/05293 (1996-02-01), None
patent: WO 98/14564 (1998-04-01), None
Sasagawa et al. Virology, 1995, vol. 206, pp. 126-135.
Buonamassa et al., “Expression of HPV 6 and 16 Capsid Proteins in Yeast and Induction of Specific IgA Response in Mice,”Virus Research,47(2):126, (1997).
Bonnez et al., “Propagation of Human Papillomavirus Type 11 in Human Xenografts Using the Severe Combined Immunodeficiency (SCID) Mouse and Comparison to the Nude Mouse Model”, Virology, (1993) 197:455-458.
Bonnez et al., “Isolation and Propagation of Human Papillomavirus Type 16 in Human Xenografts Implanted in the Severe Combined Immunodeficiency Mouse”, J. Virol., (Jun. 1998) 72(6):5256-5261.
Chan et al., “Phylogenetic Analysis of 48 Papillomavirus Types and 28 Subtypes and Variants: A Showcase for the Molecular Evolution of DNA Viruses”, J. Virol., (Oct. 1992) 66(10):5714-5725.
Chang et al., “Phenotypic Mixing Between Different Hepadnavirus Nucleocapsid Proteins Reveals C Protein Dimerization To Be Cis Preferential”, J. Virol., (Aug. 1994) 68(8):5225-5231.
Christensen et al., “Antibody-Mediated Neutralization In Vivo of Infectious Papillomaviruses”, J. Virol., (Jul. 1990) 64(7):3151-3156.
Christensen et al., “Monoclonal Antibody-Mediated Neutralization of Infectious Human Papillomavirus Type 11”, (1990) 64(11):5678-5681.
Christensen et al., “Human Papillomavirus Types 6 and 11 Have Antigenically Distinct Strongly Immunogenic Conformationally Dependent Neutralizing Epitopes”, Virology, (1994) 205:329-335.
Christensen et al., “Monoclonal Antibodies to HPV-6 L1 Virus-like Particles Identify Conformational and Linear Neutralizing Epitopes on HPV-11 in Addition to Type-Specific Epitopes on HPV-6”, Virology, (1996) 224:477-486.
Christensen et al., “Surface Conformational and Linear Epitopes on HPV-16 and HPV-18 L1 Virus-like Particles as Defined by Monoclonal Antibodies”, Virology, (1996) 223:174-184.
Deminie et al., “Incorporation of Human Immunodeficiency Virus Type 1 Gag Proteins into Mufine Leukemia Virus Virions”, J. Virol., (1993) 67(11):6499-6506.
Doorbar et al., “Identification of Proteins Encoded by the L1 and L2 Open Reading Frames of Human Papillomavirus 1A”, J. Virol., (Sep. 1987) 61(9):2793-2799.
Firzlaff et al., “Detection of Human Papillomavirus Capsid Antigens in Various Squamous Epithelial Lesions Using Antibodies Directed Against the L1 and L2 Open Reading Frames”, Virology, 164:467-477.
Franke et al., “Specificity and Sequence Requirements for Interactions Between Various Retroviral Gag Proteins”, J. Virol., (Aug. 1994) 68(8):5300-5305.
Greer et al., “Human Papillomavirus (HPV) Type Distribution and Serological Response to HPV Type 6 Virus-Like Particles in Patients with Genital Warts” (Aug. 1995) J. Clinical Microbiology 33(8):2058-2063.
Hagensee et al., “Self-Assembly of Human Papillomavirus Type 1 Capsids by Expression of L1 Protein Alone or by CoExpression of the L1 and L2 Capsid Proteins”, J. Virol., (Jan. 1993) 67(1):315-322.
Hagensee et al., “Three-Dimensional Structure of Vaccinia Virus-Produced Human Papillo mavirus Type 1 Capsids”, J. of Virol., (Jul. 1994) 68(7):4503-4505.
Hines et al., “The Expression and Processing of Human Beta-Amyloid Peptide Precursors inSaccharomyces cerevisae: Evidence for a Novel Endopeptidase in the Yeast Secretory System”, Cell. Mol. Biol. Res., (1994) 40(4):273-284.
Hofmann et al., “Sequence Determination of Human Papillomavirus 6A and Assembly of Virus-like Particles inSaccharomyces cerevisae”, Virology, (1995) 209:506-518.
Hofmann et al., “Sequence Conservation Within the Major Capsid Protein of Human Papillomavirus (HPV) Type 18 and Formation of HPV-18 Virus-like Particles inSaccharomyces cerevisiae”, J. Gen. Virol., (1996) 77:465-468.
Jansen et al., “Vaccination with Yeast-Expressed Cottontail Rabbit Papillomavirus (CRPV) Virus-like Particles Protects Rabbits from CRPV-Induced Papilloma Formation”, Vaccine, (1995) 13(16):1509-1514.
Kirnbauer et al., “Papillomavirus L1 Major Capsid Protein Self-Assembles Into Virus-like Particles That Are Highly Immunogenic”, Proc. Natl. Acad. Sci. USA, (1992) 89:12180-12184.
Kirnbauer et al., “Efficient Self-Assembly of Human Papillomavirus Type 16 L1 and L1-L2 Into Virus-like Particles”, J. Virol., (1993) 67(12):6929-6936.
Kirnbauer et al., “Virus-Like Particles of Bovine Papillomavirus Type 4 In Prophylactic and Therapeutic Immunization”, Virology, (1996) 219:37-44.
Kreider et al., “Laboratory Production In Vivo of Infectious Human Papillomavirus Type 11”, (1 J. Virol., (Feb. 1987) 61(2):590-593.
Li et al., “Expression of the Human Papillomavirus Type 1l L1 Capsid Protein inEscherichia coli: Characterization of Protein Domains Involved in DNA Binding and Capsid Assembly”, J. Virol., (Apr. 1997) 71(4):2988-2995.
Li et al., “Intercapsomeric Disulfide Bonds in Papillomavirus Assembly and Disassembly”, J. Virol., (Mar. 1998) 72(3):2160-2167.
Lowe et al., “Human Papillomavirus Type 11 (HPV-11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like Particles Expressed in Yeast”, J. Infect. Dis., (1997) 176:1141-1145.
Muller et al., “Papillomavirus Capsid Binding and Uptake by Cells from Different Tissues and Species”, J. Virol., (Feb. 1995) 69(2):948-954.
Neeper et al., “Expression of the Major Capsid Protein of Human Papillomavirus Type 11 inSaccharomyces cerevisae”, Gene, (1996) 180:1-6.
Ott et al., Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines (1995) in M.F. Powell and M. J. Newman (ed.), Vaccine Design., The subunit and adjuvant approach. (1995) 277-296 Plenum Press, New York, N.Y.
Qi et al., “Epithelial Cells Display Separate Receptors for Papillomavirus VLPs and for Soluble L1 Capsid Protein”, Virology, (1996) 216:35-45.
Roden et al., “Neutralization of Bovine Papillomavirus by Antibodies to L1 and L2 Capsid Proteins”, J. Virol., (Nov. 1997) 68(11):7570-7574.
Roden et al., “Interaction of Papillomaviruses with the Cell Surface”, J. Virol., (Nov. 1994) 68(11):7260-7266.
Roden et al., “In Vitro Generation and Type-Specific Neutralization of a Human Papillomavirus Type 16 Virion Pseudotype”, J. Virol., (Sep. 1996) 70(9):5875-5883.
Roden et al., “Assessment of Serological Relatedness of Genital Human Papillomavirus by Hemagglutination Inhibition”, J. Virol., (May 1996) 70(5):3298-3301.
Rose et al., “Serological Differentiation of Human Papillomavirus Types 11, 16, and 18 Using Recombinant Virus-Like Particles”, J. Gen. Virol., (1994) 75:2445-2449.
Rose et al., “Expression of Human Papillomavirus Type 11 L1 Protein in Insect Cells: In Vivo and In Vitro Assembly of Virus-like Particles”, J. Virol., (Apr. 1993) 67(4):1936-1944.
Sapp et al., “Organization of the Major and Minor Capsid Proteins in Human Papillomavirus Type 33 Virus-like Particles”, J. Gen. Virol., 76: 2407-2412.
Sapp et al., “Papillomavirus Assembly Requires Trimerization of the Major Capsid Protein by Disulfides Between Two Highly Conserved Cysteines”, J. Virol., (Jul. 1998) 72 (7):6186-6189.
Smith et al., “Titration of HPV-11 Infectivity and Antibody Neutralization Can Be Measured In Vit
Bensi Giuliano
Buonamassa Daniela Tornese
Galeotti Cesira L.
Greer Catherine E.
Petracca Roberto
Chiron Corporation
Hale Rececca M.
Harbin Alisa A.
Robins Roberta L.
Salimi Ali R.
LandOfFree
Method for producing yeast expressed HPV types 6 and 16... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for producing yeast expressed HPV types 6 and 16..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for producing yeast expressed HPV types 6 and 16... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3609477